Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • From JHM
  • Industry Content
    • Patient Monitoring with Tech

No mortality benefit after intensive glucose control once Hb A1c curves equalize

Background: A previous study reported that a median of 5.6 years of intensive versus standard glucose lowering in veterans with type 2 diabetes resulted in significantly reduced risk of major cardiovascular events after 10 years of combined intervention and observational follow-up.

Dr. Jessica Burke is a hospitalist at Vanderbilt University Medical Center, Nashville, Tenn.

Dr. Jessica Burke


Study design: Prospective cohort.

Setting: Veterans Affairs Healthcare System.

Synopsis: In the original trial, 1,791 veterans were randomly assigned to receive either intensive or standard glucose control therapy. After conclusion of that study, 1,655 participants were followed using central databases, and 1,391 also provided data via surveys and chart review. Initially the difference in the glycated hemoglobin (Hb A1c) curves between the two groups averaged 1.5%, but it declined to 0.2%-0.3% 3 years after the trial ended. The median Hb A1c then stabilized to 8% in both groups.

Over a period of 15 years of combined intervention and posttrial follow-up, the risks of major cardiovascular events or death were not lower in the intensive-therapy group (hazard ratio for composite outcome, 0.91; 95% confidence interval, 0.78-1.06; P = .23; HR for death, 1.02; 95% CI, 0.88-1.18). The risk of major cardiovascular disease outcomes was reduced during the approximately 10-year interval of separation of the Hb A1c curves (HR, 0.83; 95% CI, 0.70-0.99), but it did not persist after equalization of Hb A1c levels (HR, 1.26; 95% CI, 0.90-1.75). Limitations include the observational study design, the study population of mostly older men, and reliance on administrative data for outcomes.

Bottom line: More than 5 years of intensive glucose lowering, compared with standard therapy, did not show significantly lower risks of cardiovascular events or mortality once the glycated hemoglobin curves equalized during follow-up in years 11-15.

Citation: Reaven PD et al. Intensive glucose control in patients with type 2 diabetes – 15-year follow-up. New Engl J Med. 2019 Jun 6;380(23):2215-24.

Dr. Burke is a hospitalist at Vanderbilt University Medical Center, Nashville, Tenn.

  • 1

    No mortality benefit after intensive glucose control once Hb A1c curves equalize

    October 23, 2020

  • 1

    COVID-19 vaccine standards questioned at FDA advisory meeting

    October 23, 2020

  • 1

    CDC expands definition of COVID-19 exposure from ‘close contact’

    October 23, 2020

  • COVID-19: Convalescent plasma falls short in phase 2 trial

    October 22, 2020

  • 1

    FDA approves remdesivir, first treatment for COVID-19

    October 22, 2020

  • 1

    Establishing a strong and lasting mentor/mentee relationship

    October 22, 2020

  • 1

    Certain statins linked to lower mortality risk in patients admitted for sepsis

    October 22, 2020

  • 1

    Rinse and repeat? Mouthwash might mitigate COVID-19 spread

    October 22, 2020

  • 1

    Patients can read your clinical notes starting Nov. 2

    October 22, 2020

  • 1

    Cardiogenic shock rate soars in COVID-positive ACS

    October 21, 2020

1 … 200 201 202 203 204 … 975
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences